Gastric Cancer – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Gastric Cancer – Pipeline Review, H2 2016’, provides an overview of the Gastric Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Gastric Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Gastric Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Gastric Cancer

The report reviews pipeline therapeutics for Gastric Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Gastric Cancer therapeutics and enlists all their major and minor projects

The report assesses Gastric Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Gastric Cancer

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Gastric Cancer

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Gastric Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

3SBio Inc.

AB Science SA

AbbVie Inc

AbGenomics International, Inc.

ADC Therapeutics Sarl

Advaxis, Inc.

Advenchen Laboratories, LLC

Agenus, Inc.

Almac Discovery Limited

Alteogen Inc.

Ambrx, Inc.

Amgen Inc.

arGEN-X BV

Asana BioSciences, LLC

Aslan Pharmaceuticals Pte Ltd

Astellas Pharma Inc.

AstraZeneca Plc

Atara Biotherapeutics, Inc.

Athenex, Inc.

Azaya Therapeutics, Inc.

Basilea Pharmaceutica Ltd.

Bayer AG

BeiGene, Ltd.

Betta Pharmaceuticals Co. Ltd.

Bionovis SA

Boehringer Ingelheim GmbH

Boston Biomedical, Inc.

Bristol-Myers Squibb Company

Calithera Biosciences, Inc.

Cancer Prevention Pharmaceuticals, Inc.

Celgene Corporation

Celldex Therapeutics, Inc.

Cellectar Biosciences, Inc.

Celltrion, Inc.

Celon Pharma Sp. z o.o.

Cerulean Pharma, Inc.

Chipscreen Biosciences Ltd

Curaxys, S.L.

DAE HWA Pharmaceutical Co., Ltd.

Daiichi Sankyo Company, Limited

Debiopharm International SA

Deciphera Pharmaceuticals, LLC

Dong-A Socio Holdings Co. Ltd.

Dr. Reddy's Laboratories Limited

Eddingpharm

EirGenix Inc.

Eli Lilly and Company

Esperance Pharmaceuticals, Inc.

F. Hoffmann-La Roche Ltd.

Five Prime Therapeutics, Inc.

Frost Biologic, Inc.

Galena Biopharma, Inc.

Genelux Corporation

Genentech, Inc.

Gilead Sciences, Inc.

GlaxoSmithKline Plc

GlycoNex Inc.

Glycotope GmbH

Green Cross Corporation

Halozyme Therapeutics, Inc.

Hanmi Pharmaceuticals, Co. Ltd.

Horizon Pharma Plc

Hutchison MediPharma Limited

Ignyta, Inc.

Immunomedics, Inc.

Imugene Limited

Incyte Corporation

Inovio Pharmaceuticals, Inc.

INSYS Therapeutics, Inc.

Intezyne Technologies, Inc.

Jiangsu Hengrui Medicine Co., Ltd.

Jiangsu Kanion Pharmaceutical Co., Ltd.

Johnson & Johnson

KaloBios Pharmaceuticals, Inc.

Karyopharm Therapeutics, Inc.

Kolltan Pharmaceuticals, Inc.

Kuhnil Pharmaceutical Co., Ltd.

Kyowa Hakko Kirin Co., Ltd.

LegoChem Biosciences, Inc

Les Laboratoires Servier SAS

MacroGenics, Inc.

MaxiVAX SA

Mebiopharm Co., Ltd.

MedImmune, LLC

Medivation, Inc.

Merck & Co., Inc.

Merck KGaA

Merrimack Pharmaceuticals, Inc.

Mersana Therapeutics, Inc.

Merus NV

Millennium Pharmaceuticals Inc

Mirna Therapeutics, Inc.

Molecular Targeting Technologies, Inc.

MolMed S.p.A.

NanoCarrier Co., Ltd.

NeuClone Pty Ltd

Novartis AG

OBI Pharma, Inc.

Omnitura Therapeutics Inc.

Oncobiologics, Inc.

Oncolys BioPharma Inc

Oncolytics Biotech Inc.

OncoMed Pharmaceuticals, Inc.

OncoTherapy Science, Inc.

Ono Pharmaceutical Co., Ltd.

Opsona Therapeutics Limited

Panacea Biotec Limited

Patrys Limited

Pfizer Inc.

Pharma Mar, S.A.

Puma Biotechnology, Inc.

Rexahn Pharmaceuticals, Inc.

Rgenix, Inc.

Rhizen Pharmaceuticals S.A.

Richter Gedeon Nyrt.

Samumed LLC

Sanofi

Sequella, Inc.

Shanghai Henlius Biotech Co., Ltd.

Shionogi & Co., Ltd.

Simcere Pharmaceutical Group

Sorrento Therapeutics, Inc.

Spectrum Pharmaceuticals, Inc.

Supratek Pharma Inc.

SynCore Biotechnology Co., Ltd.

Synovo GmbH

Synthon Holdings BV

Taiho Pharmaceutical Co., Ltd.

Taiwan Liposome Company, Ltd.

Takeda Pharmaceutical Company Limited

Takis S.r.l.

Tara Immuno-Oncology Therapeutics LLC

Tessa Therapeutics Pte Ltd

Transgene SA

United BioPharma, Inc.

Vaxon Biotech

XuanZhu Pharma Co., Ltd.

Zymeworks Inc.

Table of Contents

Table of Contents

Table of Contents 2

Introduction 9

Gastric Cancer Overview 10

Therapeutics Development 11

Gastric Cancer - Therapeutics under Development by Companies 13

Gastric Cancer - Therapeutics under Investigation by Universities/Institutes 24

Gastric Cancer - Pipeline Products Glance 25

Gastric Cancer - Products under Development by Companies 29

Gastric Cancer - Products under Investigation by Universities/Institutes 45

Gastric Cancer - Companies Involved in Therapeutics Development 46

Gastric Cancer - Therapeutics Assessment 184

Drug Profiles 214

Gastric Cancer - Dormant Projects 911

Gastric Cancer - Discontinued Products 924

Gastric Cancer - Product Development Milestones 928

Appendix 935

List of Tables

List of Tables

Number of Products under Development for Gastric Cancer, H2 2016 38

Number of Products under Development for Gastric Cancer – Comparative Analysis, H2 2016 39

Number of Products under Development by Companies, H2 2016 40

Number of Products under Development by Companies, H2 2016 (Contd..1) 41

Number of Products under Development by Companies, H2 2016 (Contd..2) 42

Number of Products under Development by Companies, H2 2016 (Contd..3) 43

Number of Products under Development by Companies, H2 2016 (Contd..4) 44

Number of Products under Development by Companies, H2 2016 (Contd..5) 45

Number of Products under Development by Companies, H2 2016 (Contd..6) 46

Number of Products under Development by Companies, H2 2016 (Contd..7) 47

Number of Products under Development by Companies, H2 2016 (Contd..8) 48

Number of Products under Development by Companies, H2 2016 (Contd..9) 49

Number of Products under Development by Companies, H2 2016 (Contd..10) 50

Number of Products under Investigation by Universities/Institutes, H2 2016 51

Comparative Analysis by Late Stage Development, H2 2016 52

Comparative Analysis by Clinical Stage Development, H2 2016 53

Comparative Analysis by Early Stage Development, H2 2016 54

Comparative Analysis by Unknown Stage Development, H2 2016 55

Products under Development by Companies, H2 2016 56

Products under Development by Companies, H2 2016 (Contd..1) 57

Products under Development by Companies, H2 2016 (Contd..2) 58

Products under Development by Companies, H2 2016 (Contd..3) 59

Products under Development by Companies, H2 2016 (Contd..4) 60

Products under Development by Companies, H2 2016 (Contd..5) 61

Products under Development by Companies, H2 2016 (Contd..6) 62

Products under Development by Companies, H2 2016 (Contd..7) 63

Products under Development by Companies, H2 2016 (Contd..8) 64

Products under Development by Companies, H2 2016 (Contd..9) 65

Products under Development by Companies, H2 2016 (Contd..10) 66

Products under Development by Companies, H2 2016 (Contd..11) 67

Products under Development by Companies, H2 2016 (Contd..12) 68

Products under Development by Companies, H2 2016 (Contd..13) 69

Products under Development by Companies, H2 2016 (Contd..14) 70

Products under Development by Companies, H2 2016 (Contd..15) 71

Products under Investigation by Universities/Institutes, H2 2016 72

Gastric Cancer – Pipeline by 3SBio Inc., H2 2016 73

Gastric Cancer – Pipeline by AB Science SA, H2 2016 74

Gastric Cancer – Pipeline by AbbVie Inc, H2 2016 75

Gastric Cancer – Pipeline by AbGenomics International, Inc., H2 2016 76

Gastric Cancer – Pipeline by ADC Therapeutics Sarl, H2 2016 77

Gastric Cancer – Pipeline by Advaxis, Inc., H2 2016 78

Gastric Cancer – Pipeline by Advenchen Laboratories, LLC, H2 2016 79

Gastric Cancer – Pipeline by Agenus, Inc., H2 2016 80

Gastric Cancer – Pipeline by Almac Discovery Limited, H2 2016 81

Gastric Cancer – Pipeline by Alteogen Inc., H2 2016 82

Gastric Cancer – Pipeline by Ambrx, Inc., H2 2016 83

Gastric Cancer – Pipeline by Amgen Inc., H2 2016 84

Gastric Cancer – Pipeline by arGEN-X BV, H2 2016 85

Gastric Cancer – Pipeline by Asana BioSciences, LLC, H2 2016 86

Gastric Cancer – Pipeline by Aslan Pharmaceuticals Pte Ltd, H2 2016 87

Gastric Cancer – Pipeline by Astellas Pharma Inc., H2 2016 88

Gastric Cancer – Pipeline by AstraZeneca Plc, H2 2016 89

Gastric Cancer – Pipeline by Atara Biotherapeutics, Inc., H2 2016 90

Gastric Cancer – Pipeline by Athenex, Inc., H2 2016 91

Gastric Cancer – Pipeline by Azaya Therapeutics, Inc., H2 2016 92

Gastric Cancer – Pipeline by Basilea Pharmaceutica Ltd., H2 2016 93

Gastric Cancer – Pipeline by Bayer AG, H2 2016 94

Gastric Cancer – Pipeline by BeiGene, Ltd., H2 2016 95

Gastric Cancer – Pipeline by Betta Pharmaceuticals Co. Ltd., H2 2016 96

Gastric Cancer – Pipeline by Bionovis SA, H2 2016 97

Gastric Cancer – Pipeline by Boehringer Ingelheim GmbH, H2 2016 98

Gastric Cancer – Pipeline by Boston Biomedical, Inc., H2 2016 99

Gastric Cancer – Pipeline by Bristol-Myers Squibb Company, H2 2016 100

Gastric Cancer – Pipeline by Calithera Biosciences, Inc., H2 2016 101

Gastric Cancer – Pipeline by Cancer Prevention Pharmaceuticals, Inc., H2 2016 102

Gastric Cancer – Pipeline by Celgene Corporation, H2 2016 103

Gastric Cancer – Pipeline by Celldex Therapeutics, Inc., H2 2016 104

Gastric Cancer – Pipeline by Cellectar Biosciences, Inc., H2 2016 105

Gastric Cancer – Pipeline by Celltrion, Inc., H2 2016 106

Gastric Cancer – Pipeline by Celon Pharma Sp. z o.o., H2 2016 107

Gastric Cancer – Pipeline by Cerulean Pharma, Inc., H2 2016 108

Gastric Cancer – Pipeline by Chipscreen Biosciences Ltd, H2 2016 109

Gastric Cancer – Pipeline by Curaxys, S.L., H2 2016 110

Gastric Cancer – Pipeline by DAE HWA Pharmaceutical Co., Ltd., H2 2016 111

Gastric Cancer – Pipeline by Daiichi Sankyo Company, Limited, H2 2016 112

Gastric Cancer – Pipeline by Debiopharm International SA , H2 2016 113

Gastric Cancer – Pipeline by Deciphera Pharmaceuticals, LLC, H2 2016 114

Gastric Cancer – Pipeline by Dong-A Socio Holdings Co. Ltd., H2 2016 115

Gastric Cancer – Pipeline by Dr. Reddy's Laboratories Limited, H2 2016 116

Gastric Cancer – Pipeline by Eddingpharm, H2 2016 117

Gastric Cancer – Pipeline by EirGenix Inc., H2 2016 118

Gastric Cancer – Pipeline by Eli Lilly and Company, H2 2016 119

Gastric Cancer – Pipeline by Esperance Pharmaceuticals, Inc., H2 2016 120

Gastric Cancer – Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 121

Gastric Cancer – Pipeline by Five Prime Therapeutics, Inc., H2 2016 122

Gastric Cancer – Pipeline by Frost Biologic, Inc., H2 2016 123

Gastric Cancer – Pipeline by Galena Biopharma, Inc., H2 2016 124

Gastric Cancer – Pipeline by Genelux Corporation, H2 2016 125

Gastric Cancer – Pipeline by Genentech, Inc., H2 2016 126

Gastric Cancer – Pipeline by Gilead Sciences, Inc., H2 2016 127

Gastric Cancer – Pipeline by GlaxoSmithKline Plc, H2 2016 128

Gastric Cancer – Pipeline by GlycoNex Inc., H2 2016 129

Gastric Cancer – Pipeline by Glycotope GmbH, H2 2016 130

Gastric Cancer – Pipeline by Green Cross Corporation, H2 2016 131

Gastric Cancer – Pipeline by Halozyme Therapeutics, Inc., H2 2016 132

Gastric Cancer – Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2016 133

Gastric Cancer – Pipeline by Horizon Pharma Plc, H2 2016 134

Gastric Cancer – Pipeline by Hutchison MediPharma Limited, H2 2016 135

Gastric Cancer – Pipeline by Ignyta, Inc., H2 2016 136

Gastric Cancer – Pipeline by Immunomedics, Inc., H2 2016 137

Gastric Cancer – Pipeline by Imugene Limited, H2 2016 138

Gastric Cancer – Pipeline by Incyte Corporation, H2 2016 139

Gastric Cancer – Pipeline by Inovio Pharmaceuticals, Inc., H2 2016 140

Gastric Cancer – Pipeline by INSYS Therapeutics, Inc., H2 2016 141

Gastric Cancer – Pipeline by Intezyne Technologies, Inc., H2 2016 142

Gastric Cancer – Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2016 143

Gastric Cancer – Pipeline by Jiangsu Kanion Pharmaceutical Co., Ltd., H2 2016 144

Gastric Cancer – Pipeline by Johnson & Johnson, H2 2016 145

Gastric Cancer – Pipeline by KaloBios Pharmaceuticals, Inc., H2 2016 146

Gastric Cancer – Pipeline by Karyopharm Therapeutics, Inc., H2 2016 147

Gastric Cancer – Pipeline by Kolltan Pharmaceuticals, Inc., H2 2016 148

Gastric Cancer – Pipeline by Kuhnil Pharmaceutical Co., Ltd., H2 2016 149

Gastric Cancer – Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2016 150

Gastric Cancer – Pipeline by LegoChem Biosciences, Inc, H2 2016 151

Gastric Cancer – Pipeline by Les Laboratoires Servier SAS, H2 2016 152

Gastric Cancer – Pipeline by MacroGenics, Inc., H2 2016 153

Gastric Cancer – Pipeline by MaxiVAX SA, H2 2016 154

Gastric Cancer – Pipeline by Mebiopharm Co., Ltd., H2 2016 155

Gastric Cancer – Pipeline by MedImmune, LLC, H2 2016 156

Gastric Cancer – Pipeline by Medivation, Inc., H2 2016 157

Gastric Cancer – Pipeline by Merck & Co., Inc., H2 2016 158

Gastric Cancer – Pipeline by Merck KGaA, H2 2016 159

Gastric Cancer – Pipeline by Merrimack Pharmaceuticals, Inc., H2 2016 160

Gastric Cancer – Pipeline by Mersana Therapeutics, Inc., H2 2016 161

Gastric Cancer – Pipeline by Merus NV, H2 2016 162

Gastric Cancer – Pipeline by Millennium Pharmaceuticals Inc, H2 2016 163

Gastric Cancer – Pipeline by Mirna Therapeutics, Inc., H2 2016 164

Gastric Cancer – Pipeline by Molecular Targeting Technologies, Inc., H2 2016 165

Gastric Cancer – Pipeline by MolMed S.p.A., H2 2016 166

Gastric Cancer – Pipeline by NanoCarrier Co., Ltd., H2 2016 167

Gastric Cancer – Pipeline by NeuClone Pty Ltd, H2 2016 168

Gastric Cancer – Pipeline by Novartis AG, H2 2016 169

Gastric Cancer – Pipeline by OBI Pharma, Inc., H2 2016 170

Gastric Cancer – Pipeline by Omnitura Therapeutics Inc., H2 2016 171

Gastric Cancer – Pipeline by Oncobiologics, Inc., H2 2016 172

Gastric Cancer – Pipeline by Oncolys BioPharma Inc, H2 2016 173

Gastric Cancer – Pipeline by Oncolytics Biotech Inc., H2 2016 174

Gastric Cancer – Pipeline by OncoMed Pharmaceuticals, Inc., H2 2016 175

Gastric Cancer – Pipeline by OncoTherapy Science, Inc., H2 2016 176

Gastric Cancer – Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 177

Gastric Cancer – Pipeline by Opsona Therapeutics Limited, H2 2016 178

Gastric Cancer – Pipeline by Panacea Biotec Limited, H2 2016 179

Gastric Cancer – Pipeline by Patrys Limited, H2 2016 180

Gastric Cancer – Pipeline by Pfizer Inc., H2 2016 181

Gastric Cancer – Pipeline by Pharma Mar, S.A., H2 2016 182

Gastric Cancer – Pipeline by Puma Biotechnology, Inc., H2 2016 183

Gastric Cancer – Pipeline by Rexahn Pharmaceuticals, Inc., H2 2016 184

Gastric Cancer – Pipeline by Rgenix, Inc., H2 2016 185

Gastric Cancer – Pipeline by Rhizen Pharmaceuticals S.A., H2 2016 186

Gastric Cancer – Pipeline by Richter Gedeon Nyrt., H2 2016 187

Gastric Cancer – Pipeline by Samumed LLC, H2 2016 188

Gastric Cancer – Pipeline by Sanofi, H2 2016 189

Gastric Cancer – Pipeline by Sequella, Inc., H2 2016 190

Gastric Cancer – Pipeline by Shanghai Henlius Biotech Co., Ltd., H2 2016 191

Gastric Cancer – Pipeline by Shionogi & Co., Ltd., H2 2016 192

Gastric Cancer – Pipeline by Simcere Pharmaceutical Group, H2 2016 193

Gastric Cancer – Pipeline by Sorrento Therapeutics, Inc., H2 2016 194

Gastric Cancer – Pipeline by Spectrum Pharmaceuticals, Inc., H2 2016 195

Gastric Cancer – Pipeline by Supratek Pharma Inc., H2 2016 196

Gastric Cancer – Pipeline by SynCore Biotechnology Co., Ltd., H2 2016 197

Gastric Cancer – Pipeline by Synovo GmbH, H2 2016 198

Gastric Cancer – Pipeline by Synthon Holdings BV, H2 2016 199

Gastric Cancer – Pipeline by Taiho Pharmaceutical Co., Ltd., H2 2016 200

Gastric Cancer – Pipeline by Taiwan Liposome Company, Ltd., H2 2016 201

Gastric Cancer – Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 202

Gastric Cancer – Pipeline by Takis S.r.l., H2 2016 203

Gastric Cancer – Pipeline by Tara Immuno-Oncology Therapeutics LLC, H2 2016 204

Gastric Cancer – Pipeline by Tessa Therapeutics Pte Ltd, H2 2016 205

Gastric Cancer – Pipeline by Transgene SA, H2 2016 206

Gastric Cancer – Pipeline by United BioPharma, Inc., H2 2016 207

Gastric Cancer – Pipeline by Vaxon Biotech, H2 2016 208

Gastric Cancer – Pipeline by XuanZhu Pharma Co., Ltd., H2 2016 209

Gastric Cancer – Pipeline by Zymeworks Inc., H2 2016 210

Assessment by Monotherapy Products, H2 2016 211

Assessment by Combination Products, H2 2016 212

Number of Products by Stage and Target, H2 2016 214

Number of Products by Stage and Mechanism of Action, H2 2016 226

Number of Products by Stage and Route of Administration, H2 2016 238

Number of Products by Stage and Molecule Type, H2 2016 240

Gastric Cancer – Dormant Projects, H2 2016 938

Gastric Cancer – Dormant Projects (Contd..1), H2 2016 939

Gastric Cancer – Dormant Projects (Contd..2), H2 2016 940

Gastric Cancer – Dormant Projects (Contd..3), H2 2016 941

Gastric Cancer – Dormant Projects (Contd..4), H2 2016 942

Gastric Cancer – Dormant Projects (Contd..5), H2 2016 943

Gastric Cancer – Dormant Projects (Contd..6), H2 2016 944

Gastric Cancer – Dormant Projects (Contd..7), H2 2016 945

Gastric Cancer – Dormant Projects (Contd..8), H2 2016 946

Gastric Cancer – Dormant Projects (Contd..9), H2 2016 947

Gastric Cancer – Dormant Projects (Contd..10), H2 2016 948

Gastric Cancer – Dormant Projects (Contd..11), H2 2016 949

Gastric Cancer – Dormant Projects (Contd..12), H2 2016 950

Gastric Cancer – Discontinued Products, H2 2016 951

Gastric Cancer – Discontinued Products (Contd..1), H2 2016 952

Gastric Cancer – Discontinued Products (Contd..2), H2 2016 953

Gastric Cancer – Discontinued Products (Contd..3), H2 2016 954

List of Figures

List of Figures

Number of Products under Development for Gastric Cancer, H2 2016 38

Number of Products under Development for Gastric Cancer – Comparative Analysis, H2 2016 39

Number of Products under Development by Companies, H2 2016 40

Number of Products under Investigation by Universities/Institutes, H2 2016 51

Comparative Analysis by Late Stage Development, H2 2016 52

Comparative Analysis by Clinical Stage Development, H2 2016 53

Comparative Analysis by Early Stage Products, H2 2016 54

Assessment by Monotherapy Products, H2 2016 211

Assessment by Combination Products, H2 2016 212

Number of Products by Top 10 Targets, H2 2016 213

Number of Products by Stage and Top 10 Targets, H2 2016 213

Number of Products by Top 10 Mechanism of Actions, H2 2016 225

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 225

Number of Products by Top 10 Routes of Administration, H2 2016 237

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 237

Number of Products by Top 10 Molecule Types, H2 2016 239

Number of Products by Stage and Top 10 Molecule Types, H2 2016 239

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports